

# Erik Boot

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2678636/erik-boot-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53  
papers

1,890  
citations

23  
h-index

43  
g-index

62  
ext. papers

2,386  
ext. citations

5.8  
avg. IF

4.28  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 53 | Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. <i>American Journal of Psychiatry</i> , <b>2014</b> , 171, 627-39 | 11.9 | 472       |
| 52 | Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , <b>2015</b> , 17, 599-609  | 8.1  | 154       |
| 51 | Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 377-85  | 14.5 | 139       |
| 50 | Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. <i>EJNMMI Research</i> , <b>2011</b> , 1, 37  | 3.6  | 130       |
| 49 | Enhanced Maternal Origin of the 22q11.2 Deletion in Velocardiofacial and DiGeorge Syndromes. <i>American Journal of Human Genetics</i> , <b>2013</b> , 92, 637  | 11   | 78        |
| 48 | Update on the 22q11.2 deletion syndrome and its relevance to schizophrenia. <i>Current Opinion in Psychiatry</i> , <b>2017</b> , 30, 191-196  | 4.9  | 61        |
| 47 | Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 1054-1063   | 11.9 | 58        |
| 46 | Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. <i>Neuropsychopharmacology</i> , <b>2008</b> , 33, 1252-8  | 8.7  | 46        |
| 45 | Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , <b>2015</b> , 167A, 639-45   | 2.5  | 43        |
| 44 | Enhanced maternal origin of the 22q11.2 deletion in velocardiofacial and DiGeorge syndromes. <i>American Journal of Human Genetics</i> , <b>2013</b> , 92, 439-47   | 11   | 39        |
| 43 | Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging. <i>American Journal of Medical Genetics, Part A</i> , <b>2010</b> , 152A, 2937-8                                 | 2.5  | 39        |
| 42 | Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 4496-4510  | 15.1 | 39        |
| 41 | Obesity in adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , <b>2017</b> , 19, 204-208   | 8.1  | 37        |
| 40 | White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. <i>Schizophrenia Research</i> , <b>2011</b> , 132, 75-83  | 3.6  | 36        |
| 39 | AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2008</b> , 35, 1350-6   | 8.8  | 34        |
| 38 | Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , <b>2017</b> , 140, 1371-1383  | 11.2 | 30        |
| 37 | Internet Safety Issues for Adolescents and Adults with Intellectual Disabilities. <i>Journal of Applied Research in Intellectual Disabilities</i> , <b>2017</b> , 30, 416-418   | 2.2  | 28        |

|    |   |      |    |
|----|---|------|----|
| 36 | Neurobiological perspective of 22q11.2 deletion syndrome. <i>Lancet Psychiatry</i> , <b>2019</b> , 6, 951-960   | 23.3 | 28 |
| 35 | Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , <b>2018</b> , 176, 936-944   | 2.5  | 26 |
| 34 | Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. <i>PLoS ONE</i> , <b>2011</b> , 6, e21685  | 3.7  | 26 |
| 33 | Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , <b>2018</b> , 90, e2059-e2067  | 6.5  | 25 |
| 32 | Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. <i>Psychopharmacology</i> , <b>2000</b> , 150, 347-8   | 4.7  | 25 |
| 31 | Functional gene-expression analysis shows involvement of schizophrenia-relevant pathways in patients with 22q11 deletion syndrome. <i>PLoS ONE</i> , <b>2012</b> , 7, e33473  | 3.7  | 24 |
| 30 | A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson's disease and schizophrenia. <i>Science Advances</i> , <b>2018</b> , 4, eaar6637   | 14.3 | 21 |
| 29 | Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val158Met polymorphism, gender and symptomatology. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 888-95                         | 4.6  | 21 |
| 28 | Striatal D <sub>2</sub> receptor binding in 22q11 deletion syndrome: an [ <sup>11</sup> C]IBZM SPECT study. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 1525-31  | 4.6  | 20 |
| 27 | All-cause mortality and survival in adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , <b>2019</b> , 21, 2328-2335  | 8.1  | 19 |
| 26 | Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159928                    | 3.7  | 16 |
| 25 | COMT Val(158) met genotype and striatal D(2/3) receptor binding in adults with 22q11 deletion syndrome. <i>Synapse</i> , <b>2011</b> , 65, 967-70   | 2.4  | 15 |
| 24 | Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders: The Power of 1. <i>Neurology</i> , <b>2021</b> , 96, 529-540  | 6.5  | 15 |
| 23 | Parkinsonism in phenylketonuria: a consequence of dopamine depletion?. <i>JIMD Reports</i> , <b>2015</b> , 20, 35-8   | 1.9  | 13 |
| 22 | Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , <b>2018</b> , 176, 2146-2159   | 2.5  | 13 |
| 21 | Startle reactivity and prepulse inhibition of the acoustic startle response are modulated by catechol-O-methyl-transferase Val(158) Met polymorphism in adults with 22q11 deletion syndrome. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 1548-60 | 4.6  | 12 |
| 20 | 22q11.2 Deletion Syndrome-Associated Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 11-16  | 2.2  | 12 |
| 19 | Serotonergic, noradrenergic and dopaminergic markers are related to cognitive function in adults with 22q11 deletion syndrome. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 1159-65  | 5.8  | 11 |

|    |  |      |   |
|----|--|------|---|
| 18 | PRODH rs450046 and proline x COMT ValMet interaction effects on intelligence and startle in adults with 22q11 deletion syndrome. <i>Psychopharmacology</i> , <b>2015</b> , 232, 3111-22  | 4.7  | 9 |
| 17 | A genetic model for multimorbidity in young adults. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 132-141  | 8.1  | 9 |
| 16 | Non-pharmacological treatment of psychiatric disorders in individuals with 22q11.2 deletion syndrome; a systematic review. <i>American Journal of Medical Genetics, Part A</i> , <b>2018</b> , 176, 1742-1747  | 2.5  | 8 |
| 15 | Low prevalence of substance use in people with 22q11.2 deletion syndrome. <i>British Journal of Psychiatry</i> , <b>2019</b> , 215, 661-667  | 5.4  | 8 |
| 14 | Functional analysis of novel genetic variation in the thyroid hormone activating type 2 deiodinase. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, E2429-36   | 5.6  | 7 |
| 13 | Pericardial and bilateral pleural effusion associated with clozapine treatment. <i>European Psychiatry</i> , <b>2004</b> , 19, 65  | 6    | 7 |
| 12 | Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review. <i>American Journal of Medical Genetics, Part A</i> , <b>2019</b> , 179, 2292-2306  | 2.5  | 5 |
| 11 | Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. <i>Psychiatry Research - Neuroimaging</i> , <b>2018</b> , 272, 65-70   | 2.9  | 5 |
| 10 | Overexpression of chromosome 15q11-q13 gene products: a risk factor for schizophrenia and associated psychoses?. <i>American Journal of Psychiatry</i> , <b>2012</b> , 169, 96-7; author reply 97  | 11.9 | 5 |
| 9  | Rare copy number variations affecting the synaptic gene DMXL2 in neurodevelopmental disorders. <i>Journal of Neurodevelopmental Disorders</i> , <b>2019</b> , 11, 3  | 4.6  | 4 |
| 8  | Possible underreporting of pathogenic variants in RAI1 causing Smith-Magenis syndrome. <i>American Journal of Medical Genetics, Part A</i> , <b>2021</b> , 185, 3167-3169  | 2.5  | 4 |
| 7  | 22q11.2 microdeletion and increased risk for type 2 diabetes. <i>EClinicalMedicine</i> , <b>2020</b> , 26, 100528  | 11.3 | 2 |
| 6  | Age-Related Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , <b>2020</b> , 35, 1239-1245   | 7    | 2 |
| 5  | Cognitive behavioral therapy in 22q11.2 deletion syndrome: A case study of two young adults with an anxiety disorder. <i>Journal of Intellectual Disabilities</i> , <b>2021</b> , 25, 695-704  | 1.8  | 1 |
| 4  | Cardiac sympathetic activity in 22q11.2 deletion syndrome. <i>International Journal of Cardiology</i> , <b>2016</b> , 212, 346-51  | 3.2  | 1 |
| 3  | Personalized medical information card for adults with 22q11.2 deletion syndrome: An initiative to improve communication between patients and healthcare providers. <i>Journal of Applied Research in Intellectual Disabilities</i> , <b>2020</b> , 33, 1534-1540 | 2.2  | 0 |
| 2  | Unexpected detection of nodular melanoma of the skin on the scalp by I-123 IBZM brain SPECT. <i>Clinical Nuclear Medicine</i> , <b>2011</b> , 36, 148-9  | 1.7  | 0 |
| 1  | Poster #106 STARTLE REACTIVITY AND PREPULSE INHIBITION OF THE ACOUSTIC STARTLE RESPONSE ARE MODULATED BY COMT VAL MET POLYMORPHISM IN ADULTS WITH 22Q11 DELETION SYNDROME. <i>Schizophrenia Research</i> , <b>2012</b> , 136, S223-S224                          | 3.6  |   |

